Photo Credit: HCC Public Information Office
Celgene Corporation (CELG) Releasing 7/27/17 BMO
The Estimize consensus calls for EPS of $1.79, two cents higher than the Wall Street consensus. Currently, the Estimize community is looking for revenues of $3.214B, slightly lower than the Street’s expectation for $3.225B.
Will Celgene be delivering an earnings surprise this quarter? Let’s take a look. During the Great Biotech Wreck in 2015, CELG is one of the few biotech stocks that held up and bounced back quickly. The loss for the industry was approximately 40%, but unlike other biotech stocks that lost close to 60%, CELG stayed below the industry index. Unfortunately, Celgene is facing some legal trouble right now. They just settled a lawsuit for $280 million after marketing two cancer drugs, Revlimid and Thalomid, for unapproved uses. On the flipside, there are many indicators that point towards a positive buy. Primarily, instead of paying out a dividend with its surplus at the end of the quarter, which settled at $8.9 billion at the end of Q1, they invest back into their pipeline. Likewise, CELG is considered a research and development ecosystem, investing and incorporating many biotech startups, as well as developing their own medicine.
